Endocrine Today Education Lab CME

World class lipid experts answer tough questions on hot topics in lipidology at the Lipid Summit in Philadelphia including the effects of various therapies on HDL-C and HDL-P, the use of HDL modulation therapies in acute coronary syndrome, the effects of CETP inhibition on HDL-C, HDL-P and HDL functionality, HDL as a marker of risk or target for therapy, the value of calculating non-HDL-C and the effects of drug therapy to reduce non-HDL-C, as well as the importance of residual risk for cardiovascular events on statin therapy and critiques on the AIM-HIGH, FIELD and ACCORD-LIPID trials.

Although new medications and combination regimens have been shown to improve glycemic control, current clinical management approaches have failed to achieve the glycemic levels most likely to provide optimal health outcomes for patients with type 2 diabetes. As the disease progresses, many patients will require additional interventions to maintain glycemic control. The challenge for clinicians is to understand how these new agents work and when they should be integrated into the current treatment paradigm for diabetes. This activity focuses on these emerging therapeutics, allowing physicians to increase their knowledge on the rationale, efficacy, safety and implementation of updated treatment algorithms.

While bariatric surgery can improve an obese patient’s overall health by limiting risk for diabetes and hypertension, patients require careful postoperative monitoring to maintain optimal health. In this activity, hear about the tests that should be ordered for postoperative patients, micronutrients that may require supplementation to avoid deficiencies, and the risk for regaining lost weight.

Bariatric surgery is a treatment option for patients with obesity. This monograph will compare and contrast the various types of surgeries. Established guidelines for selection of patients who are candidates for bariatric surgery will be reviewed. Appropriate follow-up care and monitoring of patients will also be discussed.

Diabetes significantly increases a patient’s risk of atherosclerotic events. In this monograph, leading clinicians will evaluate and explain how the implementation of therapeutic lifestyle changes, diet, and exercise along with appropriate medication can improve HDL levels and attenuate cardiovascular risk in the patient with type 2 diabetes. The safety and efficacy of treatment strategies for dyslipidemia concomitant to diabetes will be addressed, including CETP inhibition, an emerging approach that increases HDL concentration and may reduce atherosclerotic events.

Overcome clinical inertia in your practice by participating in a dynamic CME program series designed to educate physicians, nurses, pharmacists, and other healthcare providers about current Type 2 Diabetes treatment guidelines. Evaluate options for glycemic control, outline current strategies, and list screening and testing recommendations to close the clinical care gaps in T2DM treatment.

This is a two-part learning series. Module I is a traditional lecture-style presentation, while Module II integrates lecture with case-based discussions. Participants can receive 1.5 credit hours per module.

Overcome clinical inertia in your practice by participating in a dynamic CME program series designed to educate physicians, nurses, pharmacists, and other healthcare providers about current Type 2 Diabetes treatment guidelines. Evaluate options for glycemic control, outline current strategies, and list screening and testing recommendations to close the clinical care gaps in T2DM treatment.

This is a two-part learning series. Module I is a traditional lecture-style presentation, while Module II integrates lecture with case-based discussions. Participants can receive 1.5 credit hours per module.

In this program designed to address obesity, one of the nation’s most significant public health crises, leading clinicians will address the impact of excess weight on a patient’s overall health, including co-morbidities such as dyslipidemia, diabetes, osteoarthritis, renal disease and sleep apnea. The latest data on obesity management strategies, from behavior modification and meal replacement to updates on pharmacotherapy and the latest devices will be presented. Specialists will also discuss their approaches to challenging clinical cases through interactive case presentations.

In this program designed to address obesity, one of the nation’s most significant public health crises, leading clinicians will address the impact of excess weight on a patient’s overall health, including co-morbidities such as dyslipidemia, diabetes, osteoarthritis, renal disease and sleep apnea. The latest data on obesity management strategies, from behavior modification and meal replacement to updates on pharmacotherapy and the latest devices will be presented. Specialists will also discuss their approaches to challenging clinical cases through interactive case presentations.

Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease (CVD). This monograph will review the classification, diagnosis, and treatment of CKD. The relationship of CKD to CVD will be discussed, along with strategies to reduce the risk of CVD in patients with CKD.